NasdaqGS:HALOBiotechs
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed?
In early August 2026, Halozyme Therapeutics reported record second-quarter results, with revenue rising to US$481 million and net income reaching US$229.91 million, alongside higher full-year 2026 revenue guidance of US$1.84 billion to US$1.91 billion.
The company also accelerated shareholder returns by completing two buyback tranches totaling 4,800,000 shares for about US$332.64 million, while signing multiple new ENHANZE collaborations that broaden its royalty base and technology...